https://www.biospace.com/article/companies-unlocking-a-new-class-of-cancer-therapies-with-sensitive-mettl3-tuning/
A great article about RNA epigenetic modification companies. Race is seemingly missed(The board's strategy seems to be working still).
@Mason14 It seems teams working on RNA modification therapy outside of Oncology. Maybe there may be value in the applications outside of oncology for Race!
Industry news, page-7
-
- There are more pages in this discussion • 1,711 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$2.01 |
Change
0.000(0.00%) |
Mkt cap ! $337.1M | |||
| Open | High | Low | Value | Volume |
| $2.04 | $2.09 | $1.92 | $669.9K | 331.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 3813 | $2.00 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.01 | 105 | 1 |
View Market Depth
| Last trade - 15.32pm 19/06/2024 (20 minute delay) ? |
| RAC (ASX) Chart |